人福医药：关于HWS117注射液获得药物临床试验批准通知书的公告

Core Points - The company, Renfu Pharmaceutical, announced that its wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute, has received the clinical trial approval notice for HWS117 injection from the National Medical Products Administration [2] Group 1 - The approval signifies a significant step in the development of HWS117 injection, indicating potential advancements in the company's product pipeline [2] - This development may enhance the company's position in the biopharmaceutical industry, potentially leading to increased market opportunities [2]